Whitehawk Therapeutics (WHWK) Competitors

$4.49 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$4.48 -0.01 (-0.22%)

As of 05/22/2026 05:00 PM Eastern

WHWK vs. EVO, SDGR, LBRX, MGTX, and XNCR

Should you buy Whitehawk Therapeutics stock or one of its competitors? MarketBeat compares Whitehawk Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Whitehawk Therapeutics include Evotec (EVO), Schrodinger (SDGR), LB Pharmaceuticals (LBRX), MeiraGTx (MGTX), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

How does Whitehawk Therapeutics compare to Evotec?

Evotec (NASDAQ:EVO) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

5.8% of Evotec shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

In the previous week, Evotec and Evotec both had 3 articles in the media. Evotec's average media sentiment score of 0.02 beat Whitehawk Therapeutics' score of -0.25 indicating that Evotec is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Evotec currently has a consensus price target of $7.00, suggesting a potential upside of 131.02%. Whitehawk Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 63.33%. Given Evotec's higher possible upside, equities research analysts clearly believe Evotec is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Whitehawk Therapeutics has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.21	-$117.12M	N/A	N/A
Whitehawk Therapeutics	$7.14M	31.10	-$20.60M	-$1.68	N/A

Whitehawk Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Summary

Evotec and Whitehawk Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Whitehawk Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	3.84	-$103.26M	-$1.41	N/A
Whitehawk Therapeutics	$7.14M	31.10	-$20.60M	-$1.68	N/A

Whitehawk Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Schrodinger presently has a consensus target price of $20.25, indicating a potential upside of 52.26%. Whitehawk Therapeutics has a consensus target price of $7.33, indicating a potential upside of 63.33%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Schrodinger and Schrodinger both had 3 articles in the media. Schrodinger's average media sentiment score of -0.04 beat Whitehawk Therapeutics' score of -0.25 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Schrodinger has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

Schrodinger beats Whitehawk Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Whitehawk Therapeutics had 2 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 3 mentions for Whitehawk Therapeutics and 1 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.00 beat Whitehawk Therapeutics' score of -0.25 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

LB Pharmaceuticals currently has a consensus target price of $38.40, indicating a potential upside of 36.56%. Whitehawk Therapeutics has a consensus target price of $7.33, indicating a potential upside of 63.33%. Given Whitehawk Therapeutics' higher probable upside, analysts clearly believe Whitehawk Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Whitehawk Therapeutics has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Whitehawk Therapeutics	$7.14M	31.10	-$20.60M	-$1.68	N/A

LB Pharmaceuticals' return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Whitehawk Therapeutics beats LB Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to MeiraGTx?

Whitehawk Therapeutics (NASDAQ:WHWK) and MeiraGTx (NASDAQ:MGTX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 7.5% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 3 articles in the media. MeiraGTx's average media sentiment score of 0.48 beat Whitehawk Therapeutics' score of -0.25 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Whitehawk Therapeutics presently has a consensus price target of $7.33, suggesting a potential upside of 63.33%. MeiraGTx has a consensus price target of $25.83, suggesting a potential upside of 179.58%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Whitehawk Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

Whitehawk Therapeutics has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	31.10	-$20.60M	-$1.68	N/A
MeiraGTx	$81.39M	10.51	-$114.20M	-$1.48	N/A

Whitehawk Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Whitehawk Therapeutics' return on equity of -79.63% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

Summary

MeiraGTx beats Whitehawk Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Xencor?

Whitehawk Therapeutics (NASDAQ:WHWK) and Xencor (NASDAQ:XNCR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Whitehawk Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Xencor	-177.10%	-28.77%	-20.52%

Whitehawk Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 63.33%. Xencor has a consensus price target of $24.50, indicating a potential upside of 116.62%. Given Xencor's higher possible upside, analysts clearly believe Xencor is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 3 articles in the media. Xencor's average media sentiment score of 0.56 beat Whitehawk Therapeutics' score of -0.25 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	31.10	-$20.60M	-$1.68	N/A
Xencor	$125.58M	6.68	-$91.92M	-$2.29	N/A

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 4.8% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Whitehawk Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Xencor has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Summary

Whitehawk Therapeutics and Xencor tied by winning 7 of the 14 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WHWK vs. The Competition

Export

Metric	Whitehawk Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$222.04M	$918.92M	$4.25B	$12.32B
Dividend Yield	N/A	4.84%	5.93%	5.28%
P/E Ratio	N/A	1.46	21.96	25.66
Price / Sales	31.10	120.05	125.30	111.99
Price / Cash	N/A	20.07	55.68	56.67
Price / Book	1.91	7.59	34.85	7.14
Net Income	-$20.60M	-$3.64M	$112.32M	$335.98M
7 Day Performance	5.65%	1.93%	2.55%	3.56%
1 Month Performance	11.41%	76.78%	3.54%	2.54%
1 Year Performance	N/A	126.62%	15.79%	35.05%

Whitehawk Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WHWK Whitehawk Therapeutics	2.9347 of 5 stars	$4.49 flat	$7.33 +63.3%	N/A	$222.04M	$7.14M	N/A	21
EVO Evotec	3.0221 of 5 stars	$2.72 +0.4%	$7.00 +157.4%	-35.9%	$965.16M	$891.97M	N/A	4,553
SDGR Schrodinger	2.9016 of 5 stars	$12.62 -1.0%	$20.25 +60.5%	-37.9%	$941.27M	$255.87M	N/A	790
LBRX LB Pharmaceuticals	1.6501 of 5 stars	$31.41 -2.8%	$37.20 +18.4%	N/A	$926.54M	N/A	N/A	16	Positive News
MGTX MeiraGTx	2.8333 of 5 stars	$9.95 -0.2%	$25.67 +158.0%	+81.2%	$922.96M	$81.39M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. EVO, SDGR, LBRX, MGTX, and XNCR

How does Whitehawk Therapeutics compare to Evotec?

Summary

How does Whitehawk Therapeutics compare to Schrodinger?

Summary

How does Whitehawk Therapeutics compare to LB Pharmaceuticals?

Summary

How does Whitehawk Therapeutics compare to MeiraGTx?

Summary

How does Whitehawk Therapeutics compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. EVO, SDGR, LBRX, MGTX, and XNCR

How does Whitehawk Therapeutics compare to Evotec?

Do institutionals & insiders believe in EVO or WHWK?

Which has more volatility and risk, EVO or WHWK?

Does the media refer more to EVO or WHWK?

Do analysts prefer EVO or WHWK?

Which has preferable earnings & valuation, EVO or WHWK?

Is EVO or WHWK more profitable?

Summary

How does Whitehawk Therapeutics compare to Schrodinger?

Which has stronger valuation & earnings, SDGR or WHWK?

Is SDGR or WHWK more profitable?

Do insiders & institutionals believe in SDGR or WHWK?

Do analysts prefer SDGR or WHWK?

Does the media refer more to SDGR or WHWK?

Which has more risk & volatility, SDGR or WHWK?

Summary

How does Whitehawk Therapeutics compare to LB Pharmaceuticals?

Does the media prefer LBRX or WHWK?

Do analysts recommend LBRX or WHWK?

Which has stronger valuation & earnings, LBRX or WHWK?

Is LBRX or WHWK more profitable?

Do institutionals and insiders have more ownership in LBRX or WHWK?

Summary

How does Whitehawk Therapeutics compare to MeiraGTx?

Do insiders and institutionals hold more shares of WHWK or MGTX?

Does the media prefer WHWK or MGTX?

Do analysts recommend WHWK or MGTX?

Which has more risk & volatility, WHWK or MGTX?

Which has preferable valuation and earnings, WHWK or MGTX?

Is WHWK or MGTX more profitable?

Summary

How does Whitehawk Therapeutics compare to Xencor?

Is WHWK or XNCR more profitable?

Do analysts prefer WHWK or XNCR?

Does the media prefer WHWK or XNCR?

Which has preferable valuation & earnings, WHWK or XNCR?

Do institutionals and insiders believe in WHWK or XNCR?

Which has more risk & volatility, WHWK or XNCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools